Investor Presentaiton
R&D milestones in 2018
Project
TresibaⓇ
XultophyⓇ
FiaspⓇ
Q1 2018
DEVOTE and SWITCH²
US regulatory decision
DUAL I Japan Phase 3a ✓
DUAL II Japan Phase 3a ✓
OzempicⓇ
Oral semaglutide
EU and Japan
regulatory decision
PIONEER 1 data
Phase 1 data
Investor Presentation
First nine months of 2018
Slide 15
Results available¹
Regulatory milestone
Q2 2018
Q3 2018
Q4 2018
EU variation application
pens
PIONEER 2, 3, 4 and 7
data
Japan submission
Japan submission
EU variation application
SUSTAIN 7
PIONEER 5 and 10 data ✓
PIONEER 8 data
PIONEER 6 and 9 data
LAI287
AM833
Phase 1 data
N8-GP
US/EU submission
N9-GP
Concizumab
Somapacitan
Diabetes
Obesity
Haemophilia
REAL 3
Phase 2, GHD data
Growth disorders
1 Expected to be published in the given quarter or in the subsequent quarterly company announcement
2 Supplemental applications to include the two SWITCH trials have been withdrawn based on interactions with FDA
GHD: Growth hormone deficiency; AGHD: Adult growth hormone deficiency
Japan regulatory decision ✓
explorer5 data
REAL 1 (extension)
Phase 3, AGHD data
Japan submission
explorer4 data
novo nordiskView entire presentation